Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-11-29

FDA Approved: XELSTRYM — Supplemental Application (Noven Therapeutics, LLC)

View source ↗

Summary

FDA approved a supplemental application for XELSTRYM (dextroamphetamine) by Noven Therapeutics, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XELSTRYM (Dextroamphetamine)

Snippet

SUPPL AP for XELSTRYM (DEXTROAMPHETAMINE)